As a model, we used an FDA-approved humanized anti-EGFR monoclonal Ab (Cetuximab, Eli Lilly and Company, Indiana, USA), binding to our new FcBP-LGA-PEI polymer, which effectively loads TNAs, forms functionalized NPs, and specifically targets PC cell lines with high expression of ERGR in vitro and in vivo. This evidence concerns the gene EGFR and pachyonychia congenita.